---
title: "Keytruda (pembrolizumab) in high-risk early-stage triple-negative breast cancer: Pharmacology questions"
description: "Pharmacology questions on Keytruda (pembrolizumab) in high-risk early-stage triple-negative breast cancer, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Mechanism, Pharmacokinetics, and Components. Questions: How does KEYTRUDA work (mechanism of action)? What is the half-life of KEYTRUDA? What are the ingredients in KEYTRUDA? 3 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/keytruda--high-risk-early-stage-triple-negative-breast-cancer/pharmacology"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T01:54:55-05:00"
---

# Keytruda (pembrolizumab) in high-risk early-stage triple-negative breast cancer: Pharmacology questions

Manufacturer: Merck Sharp & Dohme LLC  
Prescribing information: [Keytruda](https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf)

## Mechanism

<a id="keytruda-mechanism"></a>

### How does KEYTRUDA work (mechanism of action)?

> “Pembrolizumab binds to the PD-1 receptor, blocking both immune-suppressing ligands, PD-L1 and PD-L2, from interacting with PD-1 to help restore T-cell response and immune response.
>
> Restoring active T-cell response could affect both normal healthy cells and tumor cells.”

Source: [KEYTRUDA: Mechanism of Action for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), captured 2026-11-08](https://www.keytrudahcp.com/resources/mechanism-of-action/#:~:text=Pembrolizumab%20binds%20to%20the%20PD%2D1,healthy%20cells%20and%20tumor%20cells.)

## Pharmacokinetics

<a id="keytruda-half-life"></a>

### What is the half-life of KEYTRUDA?

> “Pembrolizumab clearance (CV%) is approximately 23% lower [geometric mean, 195 mL/day (40%)] at
> steady state than that after the first dose [252 mL/day (37%)]; this decrease in clearance with time is not
> considered clinically important. The terminal half-life (t1/2) is 22 days (32%).”

Source: [KEYTRUDA: Prescribing information, page 88, captured 2026-11-13](https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf#page=88)

## Components

<a id="keytruda-ingredients"></a>

### What are the ingredients in KEYTRUDA?

> “Each vial contains 100 mg of pembrolizumab in 4 mL of
> solution. Each 1 mL of solution contains 25 mg of pembrolizumab and is formulated in: L-histidine
> (1.55 mg), polysorbate 80 (0.2 mg), sucrose (70 mg), and Water for Injection, USP.”

Source: [KEYTRUDA: Prescribing information, page 87, captured 2026-11-13](https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf#page=87)

## Related pages
- [Medical information: Keytruda (pembrolizumab): High-risk early-stage triple-negative breast cancer](https://www.evicenter.com/medical-information/keytruda--high-risk-early-stage-triple-negative-breast-cancer)
- [Indication](https://www.evicenter.com/medical-information/keytruda--high-risk-early-stage-triple-negative-breast-cancer/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/keytruda--high-risk-early-stage-triple-negative-breast-cancer/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/keytruda--high-risk-early-stage-triple-negative-breast-cancer/safety)
- [Specific populations](https://www.evicenter.com/medical-information/keytruda--high-risk-early-stage-triple-negative-breast-cancer/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/keytruda--high-risk-early-stage-triple-negative-breast-cancer/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/keytruda--high-risk-early-stage-triple-negative-breast-cancer/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/keytruda--high-risk-early-stage-triple-negative-breast-cancer/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/keytruda--high-risk-early-stage-triple-negative-breast-cancer/guidelines)
